A Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer (mCRPC)

Trial Profile

A Phase 2 study to evaluate the safety and efficacy of Opdivo in combination with Rubraca in patients with metastatic castration-resistant prostate cancer (mCRPC)

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; Rucaparib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Aug 2017 New trial record
    • 31 Jul 2017 According to a Bristol-Myers Squibb media release, this trial is expected to begin before the end of 2017. This trial may be conducted in other countries in addition to US and Europe. This trial will be conducted as an arm of a larger Bristol-Myers Squibb-sponsored study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top